Biology subjects

Veillette, A.

Publications and source records attributed to Veillette, A..

5 recordsLinked to original sources

bioRxiv2025

Binding of inhibitory checkpoints to CD18 in cis hinders anti-cancer immune responses

SIRP is an inhibitory receptor on macrophages that limits phagocytosis and anti-tumor activity of macrophages by "trans" interacting with CD47 on tumor cells. Herein, we found that a large component of SIRPs inhibitory function occurred independently of CD47-binding and phosphatase signaling. This function resulted from a direct interaction between SIRP and CD18 ({beta}2 integrin) in "cis" at the surface of macrophages, involving SIRP amino acids distinct from those implicated in the SIRP-CD47 interaction. The cis interaction prevented activation of CD18, which is necessary for phagocytosis. Combined blockade of SIRP-CD18 and SIRP-CD47 was essential for maximizing phagocytosis and suppression of tumor growth in vivo. Similar cis interactions between CD18 and other inhibitory checkpoints, including PD-1, were also observed. Thus, in addition to mediating effects when engaged by ligands in trans, inhibitory checkpoints suppress immune cell activation through a mechanism targeting CD18 in cis. This dual mode of action should be considered when developing blockers of inhibitory checkpoints for immunotherapy. One-Sentence SummaryIn addition to being engaged in "trans" by ligands on tumor cells, inhibitory receptors, such as SIRP and PD-1, hinder anti-cancer immune responses by "cis" interacting with {beta}2 integrin CD18.

immunology↗

bioRxiv2024

Bona fide cytotoxic iNKT cells with superior antitumour responses identified in mice and humans

Adoptive cell therapies (ACT) using unmodified or engineered invariant Natural Killer T (iNKT) cells are in clinical trials for cancer treatment. While promising, outcomes are still suboptimal, possibly due to iNKT cell heterogeneity. This study identified unique iNKT cell populations with strong cytotoxic activity in mice and humans. In mice, iNKT1c cells showed potent CD1d-dependent and -independent antitumor functions, with responses influenced by NK receptors. IL-15 enhances their cytolytic activity, while retinoic acid is essential for their generation. In humans, terminally differentiated CD57+ iNKT cells showed marked NK-receptor expression and most effectively killed C1R tumor cells in vitro. These cells appeared activated/exhausted within tumors of non-small cell lung cancer patients. Additionally, a central memory-like CD62L+ CD4- iNKT subset efficiently expanded and generated cytotoxic CD57+ iNKT cells in vitro, making them an appealing candidate for ACT. This study paves the way for the design of more effective iNKT cell-based immunotherapies.

immunology↗

bioRxiv2020

Alternative splicing of SLAMF6 in human T cells creates a co-stimulatory isoform that counteracts the inhibitory effect of the full-length receptor

SLAMF6 is a homotypic receptor of the Ig-superfamily associated with progenitor exhausted T cells. In humans, SLAMF6 has three splice isoforms involving its V-domain. While the canonical 8-exon receptor inhibits T cell activation through SAP recruitment, the short isoform SLAMF6{Delta}17-65 has a strong agonistic effect. The costimulatory action depends on protein phosphatase SHP-1 and leads to a cytotoxic molecular profile governed by transcription factors Tbet, Runx3, and Tcf7. In T cells from individual patients treated with immune checkpoint blockade, a shift was noted towards SLAMF6{Delta}17-65. Splice-switching antisense oligonucleotides designed to target the SLAMF6 splice junction, enhanced SLAMF6{Delta}17-65 in human tumor-infiltrating lymphocytes and improved their capacity to inhibit human melanoma in mice. The possible emergence of two opposing isoforms from the SLAMF6 gene may represent an immune-modulatory mechanism that can be exploited for cancer immunotherapy.

immunology↗

bioRxiv2019

SLAMF6 deficiency augments tumor killing and skews towards an effector phenotype revealing it as a new T cell checkpoint

SLAMF6 is a homotypic receptor of the Ig-superfamily whose exact role in immune modulation has remained elusive. Its constitutive expression on resting and activated T cells precludes it from being a bona fide exhaustion marker. By breeding Pmel-1 mice with SLAMF6 KO mice, we generated donors for T cells lacking SLAMF6 and expressing a transgenic TCR for gp100-melanoma antigen. Activated Pmel-1xSLAMF6 KO CD8 T cells displayed improved polyfunctionality and strong tumor cytolysis. T-bet was the dominant transcription factor in Pmel-1xSLAMF6 KO cells, and upon activation, they acquired an effector-memory phenotype. Blocking LAG-3 improved the function of SLAMF6 deficient T cells even further. Finally, adoptive transfer of Pmel-1xSLAMF6 KO T cells into melanoma-bearing mice resulted in lasting tumor regression in contrast to temporary responses achieved with Pmel-1 T cells. These results support the notion that SLAMF6 is an inhibitory immune receptor whose absence enables powerful CD8 T cells to eradicate tumors.

physiology↗

bioRxiv2019

Critical role for Slam/SAP signaling in the thymic developmental programming of IL-17- and IFN-γ-producing γδ T cells

During thymic development, {gamma}{delta} T cells commit to either an IFN-{gamma}- or an IL-17-producing phenotype through mechanisms that remain unclear. Here, we investigated whether the SLAM/SAP signaling pathway played a role in the functional programming of thymic {gamma}{delta} T cells. Characterization of SLAM family receptor expression revealed that thymic {gamma}{delta} T cell subsets were each marked by distinct co-expression profiles of SLAMF1, SLAMF4, and SLAMF6. In the thymus, immature CD24hi V{gamma}1 and V{gamma}4 {gamma}{delta} T cells were largely contained within a SLAMF1+SLAMF6+ double positive (DP) population, while mature CD24low subsets were either SLAMF1+ or SLAMF6+ single positive (SP) cells. In the periphery, SLAMF1 and SLAMF6 expression on V{gamma}1, V{gamma}4, and V{gamma}6 T cells distinguished IL-17- and IFN-{gamma}-producing subsets, respectively. Disruption of SLAM family receptor signaling through deletion of SAP resulted in impaired thymic {gamma}{delta} T cell maturation at the CD24hiSLAMF1+SLAMF6+ DP stage that was associated with a decreased frequency of CD44+ROR{gamma}t+ {gamma}{delta} T cells. These defects were in turn associated with impaired {gamma}{delta} T cell IL-17 and IFN-{gamma} production in both the thymus as well as in peripheral tissues. The role for SAP was subset-specific, as V{gamma}1, V{gamma}4, V{gamma}5, but not V{gamma}6 subsets were SAP-dependent. Together, these data suggest that the SLAM/SAP signaling pathway regulates a critical checkpoint in the functional programming of IL-17 and IFN-{gamma}-producing {gamma}{delta} T cell subsets during thymic development.

immunology↗